Perrigo 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Perrigo’s Q3 2026 core net sales declined 1.7% year over year, while core organic net sales declined 1.1%; all-in net sales were $989 million, down 5.2%.
- Core adjusted operating margin was 14.3%, down 210 basis points, and core adjusted earnings per share was $0.61, down $0.06 from the prior year; all-in adjusted diluted earnings per share was $0.60, down $0.20.
- Core net sales declines moderated from 8.3% in the 1st quarter to 3.1% in the 2nd quarter and 1.7% in the 3rd quarter, while core adjusted operating margin increased from 12.8% to 13.4% to 14.3%.
- U.S. store brand OTC volume grew 2% in the quarter and gained 30 basis points of share; value sales in Perrigo’s key European brands grew 6.5% and gained 80 basis points of share.
- Q3 cash from operating activities was $96 million, capital expenditures were $18 million, and Perrigo returned $40 million to shareholders through dividends; cash and cash equivalents were $437 million and total debt was $3.3 billion.
- The operational enhancement program generated $42 million of savings year to date, including $19 million in Q3, and remains on track to deliver approximately $60 million to $80 million in 2026. Core adjusted gross margin declined 140 basis points to 37.9%.
- The infant formula business had net sales decrease 9.6%; the announced divestment will result in infant formula being reported as discontinued operations beginning with Q4 and full year 2026 reporting.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Perrigo third quarter 2026 financial results conference call. At this time, our lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on Wednesday, November 4, 2026. I would now like to turn the conference over to Eric Jacobson, Vice President, Global Investor Relations.
Please go ahead, sir. Good morning and good afternoon, everyone.
Welcome to Perrigo's third quarter 2026 earnings conference call. A copy of the release we issued today and the accompanying presentation are available within the Investors section of the perrigo.com website. Joining today's call are Perrigo's Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra. As a reminder, we recently announced an agreement to divest our infant formula business. Beginning with the fourth quarter and full year 2026 reporting, the infant formula business will be reported as discontinued operations. Accordingly, the company's all-in outlook no longer includes infant formula. The company's core outlook continues to exclude infant formula and previously announced divestitures. During this presentation, participants will make certain forward-looking statements. Please refer to the slides for information regarding these statements, which are subject to important risks and uncertainties. We will reference adjusted financial measures that are non-GAAP in nature.
See the appendix to the earnings presentation for additional details and reconciliations of all non-GAAP to GAAP financial measures presented. Moving to the agenda. Albert will begin with his perspective on Perrigo and the priorities he has identified. He will then discuss our third quarter performance, progress against the Three-S plan, and the commercial opportunities he sees to drive stronger, more consistent growth. Eduardo will then provide a financial review and discuss our 2026 outlook. With that, I'll turn it over to Albert.
Thanks, Eric. Good morning, good afternoon, and thank you for joining today's call. Over my first five months at Perrigo, I have spent a significant amount of time listening to our customers, our consumers, and our people, digging into the business and our capabilities, and developing a deeper understanding of what we do well and where we can be better. And I have been increasingly impressed. We have leading store brand products, strong brands, attractive positions across our categories, and a talented organization that knows the consumer self-care business exceptionally well. I want to thank our teams across Perrigo for their hard work, commitment, and the way they have welcomed me. At the same time, it has become clear why those strengths have not translated consistently into the results we should be delivering. Over time, Perrigo has become too complex.
The business has not been integrated to the degree it needs to be, and that complexity has made it harder for our teams to execute with the necessary speed and focus. We are taking decisive action to simplify and strengthen Perrigo, and that process is a major focus for me. That means being extremely deliberate about where we invest, the businesses and geographies where we play, and how we organize ourselves. We want our talented teams focused on the areas where Perrigo has the greatest right to win and where we see the most attractive risk-adjusted returns. This work is underway, and you will hear throughout today's call how we are sharpening our focus, simplifying the business, and positioning Perrigo to deliver more consistently over time. Looking at our key takeaways from the quarter. First, our Three-S plan is working.
There is more to do, but operating performance improved sequentially, and we are making progress in the areas we control. The sale of infant formula is an important step. It simplifies our portfolio and operations, improves our margin profile, reduces expected future CapEx, and allows us to focus our people and resources where we have the greatest right to win. Competitively, we gained share again in U.S. store brand OTC and across our key European brands. Category trends also continue to improve sequentially, even as the consumer environment remain challenging in certain areas. Finally, we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. While cough and cold incidence trends have shown early signs of improvements, retailers have taken a more measured approach to inventory.
Eduardo will take you through the details later in the call, including the key drivers underlying our expectation for the balance of the year. Turning briefly to our third quarter financial results. As you can see, our results continue to reflect some of the ongoing challenges we have discussed, including retailer inventory positioning and lower contract volumes. The key takeaway for me is straightforward. The areas we control are improving, even as external headwinds continue to weigh on the reported results. You can see that more clearly in the sequential trends. Our operating performance has improved each quarter this year. The year-over-year decline in core net sales has moderated from 8.3% in the first quarter to 3.1% in the second quarter to 1.7% in the third quarter. At the same time, core adjusted operating margin continued to trend upward, increasing from 12.8% to 13.4% to 14.3%. That is meaningful progress. Category trends are improving, and the actions we are taking through our Three-S plan are having an impact.
Our job now is to build on it, continue simplifying Perrigo, and translate that progress into more consistent results. In addition to the sequential improvement in our operating performance, we are seeing the category environment improve as well. As you can see, consumption trends have strengthened from the beginning of the year in both the U.S. and Europe. In the U.S., category volume returned to modest growth in the third quarter, while in Europe, consumer trends remain soft, but the rate of decline continued to improve sequentially, and so is our execution. Turning now to the details of our recent progress. Under stabilize, operations are becoming more consistent, and service is improving, which is strengthening our relationships and increasing collaboration with our retail customers.
Under streamline, we are making clear choices about where Perrigo should compete. We have sold Dermacosmetics and announced the divestment of infant formula while continuing the strategic review of oral care. We are taking cost out. Our Operational Enhancement Program has generated $42 million of savings year to date and remains on track to deliver approximately $60 million-$80 million in 2026. Under strengthen, we are putting more investment behind innovation, demand generation, and the parts of the portfolio where we see the greatest opportunity. We are seeing the results in our share performance in U.S. store brand OTC and across our key European brands. As we simplify Perrigo, we can enhance our focus on driving growth. These are three areas where I see clear opportunities. First, innovation. We are directing innovation resources on categories where we have a right to win and where differentiated products can create meaningful value for consumer and customers.
Second, distribution. Store brand is a core Perrigo strength, and we have opportunities to put more of our products in front of more consumers. That includes e-commerce, where our market share is already higher than in the total market. I will come back to that shortly. Third, demand generation. We are investing behind the brands, products, and customer programs where we believe we can generate attractive returns. That means stronger customer partnerships and more effective consumer engagement. The objective is simple: gain share and outgrow our categories. Let me bring some of those growth building blocks to life with a few examples. In store brands, we continue to find new ways to support consumers and create value for our retail partners.
Our GLP-1 activation is a good example, where we are positioning our digestive health portfolio to support consumers along their GLP-1 journey while deepening our strategic relationship with customers. Importantly, initiatives like this one shift more of our business into faster-growing parts of the category. At the same time, our investments behind key brands are translating into strong growth and share performance. Compeed, Opill, ellaOne, Jungle Formula, all deliver growth and gain share, demonstrating the opportunity we have when we put focused investment behind differentiated brands. These examples demonstrate the strengths of both sides of Perrigo. We have a differentiated store brand portfolio and brands with meaningful growth opportunities. As I mentioned earlier, e-commerce is a particularly attractive opportunity for Perrigo. The channel is growing faster than the broader category, and our share in e-commerce is higher than our share of the total market. That matters. As more consumer purchasing moves online, we should benefit to a greater extent.
We are seeing it already. U.S. e-commerce total category volume is up nearly 15% year to date, and e-commerce now represents 22% of our U.S. volume, up from approximately 13% in 2022. We have a strong position in a growing channel. Our job is to build on it. The clearest evidence that the Three-S plan is working is our share performance. In U.S. store brand OTC, volume grew 2% in the quarter, and we gained 30 basis points of share. In Europe, value sales in our key brands grew 6.5%, well ahead of their categories, and gained 80 basis points of share. Those are important proof points. We have more opportunity in front of us, but where we are investing and executing well, we are winning. Let me close with where I am focused.
We need to build on the share momentum we're seeing and continue expanding access to high-quality, affordable self-care products. We need to keep simplifying Perrigo. The sale of infant formula is an important step, and there is more to do. We need to strengthen the balance sheet and create greater financial flexibility. To ensure our capital allocation framework remains aligned with our strategy and market opportunities, we regularly review the most effective uses of capital across growth investments, debt reduction, and shareholder returns, including assessing the dividend on a quarterly basis. We need to deliver. We have work ahead of us, but I believe we have the portfolio, the capabilities, and the people to do it. With that, I will turn it over to Eduardo to walk through the financial results in more detail.
Thank you, Albert. I appreciate everyone joining us today. Other than for references to net sales, my comments will focus on adjusted non-GAAP results unless otherwise noted. Turning to our Q3 results, starting with the top line. Core net sales declined 1.7% year-over-year, while core organic net sales declined 1.1%. Importantly, as Albert highlighted, this marks another quarter of sequential improvement, reflecting both continued execution of our Three-S plan and improving category trends across several of our key markets. Third quarter results continued to reflect a softer consumption environment. The softness, which was particularly evident in our European business, contributed to more measured retailer inventory positioning ahead of the cough and cold season within the self-care segment. These factors represented approximately a 2 percentage point headwind to growth. Lower contract manufacturing volumes created an additional headwind of roughly 1 percentage point.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
